



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|-----------|---|
| (51) International Patent Classification ⁵ : A61K 31/41, 31/415 | A1 | (11) International Publication Number: WO 92/10182 (43) International Publication Date: 25 June 1992 (25.06.92) |
| (21) International Application Number: PCT/GB91/02220 (22) International Filing Date: 12 December 1991 (12.12.91) (30) Priority data: 9017210.5 14 December 1990 (14.12.90) GB (71) Applicant (for all designated States except US): SMITH-KLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). (72) Inventor; and (75) Inventor/Applicant (for US only) : HILL, James [GB/GB]; SmithKline Beecham plc, New Horizons Court, Brentford, Middlesex TW8 9EP (GB). | | (74) Agents: THOMPSON, Clive, B. et al.; Corporate Patents, SmithKline Beecham, Mundells, Welwyn Garden City, Hertfordshire AL7 1EY (GB). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), MC (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| (54) Title: USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF DIABETIC NEPHROPATHY (57) Abstract The present invention relates to the use of an angiotensin II receptor antagonist in the manufacture of a medicament for the treatment of diabetic nephropathy. | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|-----|--------------------------|----|--|-----------------|--------------------------|
| AT | Austria | ES | Spain | MG | Madagascar |
| AU | Australia | FI | Finland | ML | Mali |
| BB | Barbados | FR | France | MN | Mongolia |
| BE | Belgium | GA | Gabon | MR | Mauritania |
| BF | Burkina Faso | GB | United Kingdom | MW | Malawi |
| BG | Bulgaria | GN | Guinea | NL | Netherlands |
| BJ | Benin | GR | Greece | NO | Norway |
| BR | Brazil | HU | Hungary | PL | Poland |
| CA | Canada | IT | Italy | RO | Romania |
| CF | Central African Republic | JP | Japan | SD | Sudan |
| CG | Congo | KP | Democratic People's Republic of Korea | SE | Sweden |
| CH | Switzerland | KR | Republic of Korea | SN | Senegal |
| CI | Côte d'Ivoire | LI | Liechtenstein | SU ⁺ | Soviet Union |
| CM | Cameroon | LK | Sri Lanka | TD | Chad |
| CS | Czechoslovakia | LU | Luxembourg | TC | Togo |
| DE* | Germany | MC | Monaco | US | United States of America |
| DK | Denmark | | | | |

⁺ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

- 1 -

MEDICAMENT

Use of angiotensin II receptor antagonists in the treatment of diabetic nephropathy.

BACKGROUND OF THE INVENTION

10 Interruption of the renin-angiotensin system (RAS) with converting enzyme inhibitors, such as captopril, has proved clinically useful in the treatment of certain disease states, such as hypertension and congestive heart failure [Abrams, et al., Federation Proc., 43:1314
15 (1984)]. Furthermore, evidence suggests that inhibition of this system may be beneficial in treating diabetic nephropathy. Since AII is the biologically active component of the renin-angiotensin system responsible for the system's peripheral effects, the most direct
20 approach towards inhibition of RAS and in particular AII-induced diabetic nephropathy would be blockade of angiotensin II at its receptor.

SUMMARY OF THE INVENTION

25 The present invention provides a new method of treatment of diabetic nephropathy in a mammal which comprises administering to a subject in need thereof an effective non-toxic amount of an angiotensin II receptor antagonist.
30 The present invention also provides for the use of an angiotensin II receptor antagonist in the manufacture of a medicament for the treatment of diabetic nephropathy.


DESCRIPTION OF THE INVENTION

35 The present invention is a therapeutic method for

- 2 -

treating diabetic nephropathy in mammals. The method utilizes a class of antagonists which have been previously prepared and evaluated as effective AII receptor antagonists. Examples of suitable angiotensin
 5 II receptor antagonists include, but are not limited to, the following:

Substituted imidazoles of the formula (I), which are described in U.S. Application Serial No. 07/746,262,
 10 filed August 14, 1991:



in which:

R^1 is adamantyl, phenyl, biphenyl, or naphthyl,
 20 with each aryl group being unsubstituted or substituted by one to three substituents selected from Cl, Br, F, I, $\text{C}_1\text{-C}_6$ alkyl, nitro, $\text{A-CO}_2\text{R}^7$, tetrazol-5-yl, $\text{C}_1\text{-C}_6$ alkoxy, hydroxy, $\text{SC}_1\text{-C}_6$ alkyl, SO_2NHR^7 , NHSO_2R^7 , SO_3H , CONR^7R^7 , CN, $\text{SO}_2\text{C}_1\text{-C}_6$ alkyl, NHSO_2R^7 , $\text{PO}(\text{OR}^7)_2$, NR^7R^7 , NR^7COH ,
 25 $\text{NR}^7\text{COC}_1\text{-C}_6$ alkyl, $\text{NR}^7\text{CON}(\text{R}^7)_2$, NR^7COW , W, SO_2W ;

m is 0-4;

R^2 is $\text{C}_2\text{-C}_{10}$ alkyl, $\text{C}_3\text{-C}_{10}$ alkenyl, $\text{C}_3\text{-C}_{10}$ alkynyl, $\text{C}_3\text{-C}_6$ cycloalkyl, or $(\text{CH}_2)_{0-8}$ phenyl unsubstituted or substituted by one to three substituents selected from
 30 $\text{C}_1\text{-C}_6$ alkyl, nitro, Cl, Br, F, I, hydroxy, $\text{C}_1\text{-C}_6$ alkoxy, NR^7R^7 , CO_2R^7 , CN, CONR^7R^7 , W, tetrazol-5-yl, $\text{NR}^7\text{COC}_1\text{-C}_6$ alkyl, NR^7COW , $\text{SC}_1\text{-C}_6$ alkyl, SO_2W , or $\text{SO}_2\text{C}_1\text{-C}_6$ alkyl;

X is a single bond, S, NR^7 , or O;

35 R^3 is hydrogen, Cl, Br, F, I, CHO, hydroxymethyl, COOR^7 , CONR^7R^7 , NO_2 , W, CN, NR^7R^7 , or phenyl;

SUBSTITUTE SHEET

- 3 -

R^4 and R^5 are independently hydrogen, C_1-C_6 alkyl, thienyl-Y-, furyl-Y-, pyrazolyl-Y-, imidazolyl-Y-, pyrrolyl-Y-, triazolyl-Y-, oxazolyl-Y-, isoxazolyl-Y-, thiazolyl-Y-, pyridyl-Y-, or tetrazolyl-Y-, except that
 5 R^4 and R^5 are not both selected from hydrogen and C_1-C_6 alkyl and each heterocyclic ring is unsubstituted or substituted by C_1-C_6 alkyl, C_1-C_6 alkoxy, Cl, Br, F, I, NR^7R^7 , CO_2R^7 , SO_2NHR^7 , SO_3H , or $CONR^7R^7$, OH, NO_2 , W, SO_2W , SC_1-C_6 alkyl, $SO_2C_1-C_6$ alkyl, NR^7COH , NR^7COW , or
 10 $NR^7COC_1-C_6$ alkyl;

Y is a single bond, O, S, or C_1-C_6 alkyl which is straight or branched or optionally substituted by phenyl or benzyl, wherein each of the aryl groups is unsubstituted or substituted by halo, NO_2 , CF_3 ,
 15 C_1-C_6 alkyl, C_1-C_6 alkoxy, CN, or CO_2R^7 ;
 R^6 is $-Z-COOR^8$ or $-Z-CONR^7R^7$;

Z is a single bond, vinyl, $-CH_2-O-CH_2-$, methylene optionally substituted by C_1-C_6 alkyl, one or two benzyl groups, thienylmethyl, or furylmethyl, or $-C(O)NHCHR^9-$,
 20 wherein R^9 is H, C_1-C_6 alkyl, phenyl, benzyl, thienylmethyl, or furylmethyl;

W is C_nF_{2n+1} , C_nF_{2n+1} , wherein n is 1-3;
 A is $-(CH_2)_m-$, $-CH=CH-$, $-O(CH_2)_n-$, or $-S(CH_2)_n-$;
 each R^7 independently is hydrogen, C_1-C_6 alkyl, or
 25 $(CH_2)_m$ phenyl, wherein m is 0-4; and
 R^8 is hydrogen, C_1-C_6 alkyl, or 2-di(C_1-C_6 alkyl)-amino-2-oxoethyl; or a pharmaceutically acceptable salt thereof.

Preferred compounds included within the scope of
 30 formula (I) are:

(E)-3-[2-n-butyl-1-{4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid,

(E)-3-[2-n-butyl-1-{4-carboxynaphth-1-yl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid,

35 (E)-3-[2-n-butyl-1-{2-chloro-4-carboxyphenyl)-methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-

SUBSTITUTE SHEET

- 4 -

propenoic acid, and

(E)-3-[2-n-butyl-1-{4-carboxy-2,3-dichlorophenyl)-methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid; or a pharmaceutically acceptable salt thereof.

Particularly preferred compounds are (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid and (E)-3-[2-n-butyl-1-{4-carboxynaphth-1-yl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid; or a pharmaceutically acceptable salt thereof.

The most preferred compound of this invention is (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid methanesulfonate.

The compounds of formula (I) are prepared following the methods described in European Patent Publication Number EP 0 403 159, published on December 19, 1990.

Substituted imidazoles, which are described in U.S. Application Serial No. 07/746,024, filed August 14, 1991, are prepared following the methods described in European Publication Number EP 0 403 158, published on December 19, 1990.

Preferred compounds included within the scope of this class of AII receptor antagonists are:

(E)-3-[2-n-butyl-1-{(2-chlorophenyl)methyl}-1H-imidazol-5-yl]-2-(3,4-methylenedioxyphenyl)methyl-2-propenoic acid,

(E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-n-butyl-2-propenoic acid, and

(E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-n-benzyl-2-propenoic acid; or a pharmaceutically acceptable salt thereof.

- 5 -

Substituted imidazoles, which are described in U.S. Application Serial No. 07/590,207, filed September 28, 1990, are prepared following the methods described in European Publication Number EP 0 425 211, published on
5 May 2, 1991.

Preferred compounds included within the scope of this class of AII receptor antagonists are:

(E)-1-[2-n-butyl-1-((4-carboxyphenyl)methyl)-1H-
10 imidazol-5-yl]-2-(1H-tetrazol-5-yl)-3-(2-thienyl)-1-propene and

(E)-1-[2-n-butyl-1-((4-(1H-tetrazol-5-yl)phenyl)-methyl)-1H-imidazol-5-yl]-2-(1H-tetrazol-5-yl)-3-(2-thienyl)-1-propene;
15 or a pharmaceutically acceptable salt thereof.

Substituted imidazoles, which are described in U.S. Serial No. 07/590,206 filed, September 28, 1990, are prepared following the methods described in European
20 Publication Number EP 0 427 463, published on May 15, 1991.

Preferred compounds included within the scope of formula (II) are:

N-[[1-(4-carboxyphenyl)methyl]-2-n-butyl-1H-
25 imidazol-5-yl)methyl]- β -(2-thienyl)alanine and

N-[[1-(2-chlorophenyl)methyl]-2-n-butyl-1H-imidazol-5-yl)methyl]- β -(2-thienyl)alanine;
or a pharmaceutically acceptable salt thereof.

30 Substituted imidazoles, which are described in U.S. Serial No. 07/621,491, filed, November 30, 1990, are prepared following the methods described in European Publication Number EP 0 437 103, published July 17, 1991.

35 Preferred compounds included within the scope of the class of AII receptor antagonist are N-[[2-n-butyl-


SUBSTITUTE SHEET

- 6 -

1- (2-chlorophenyl)methyl-1H-imidazol-5-yl)methyl-carbonyl]-L-phenylalanine and N-[(2-n-butyl-1-(2-chlorophenyl)methyl-1H-imidazol-5-yl)methylcarbonyl]-L-(2-thienyl)alanine; or a pharmaceutically acceptable
 5 salt thereof.

Substituted imidazoles of the formula (II):

10



15 in which:

R^1 is adamantyl, or phenyl, biphenyl, or naphthyl, with each aryl group being unsubstituted or substituted by one to three substituents selected from Cl, Br, F, I, $\text{C}_1\text{-C}_6$ alkyl, nitro, CO_2R^7 , tetrazol-5-yl, $\text{C}_1\text{-C}_6$ alkoxy, hydroxy, $\text{SC}_1\text{-C}_6$ alkyl, $\text{SO}_2\text{NR}^7\text{R}^7$, NHSO_2R^7 , SO_3H , CONR^7R^7 , CN, $\text{SO}_2\text{C}_1\text{-C}_6$ alkyl, or $\text{C}_n\text{F}_{2n+1}$;

20 R^2 is $\text{C}_2\text{-C}_{10}$ alkyl unsubstituted or substituted by CO_2H , OH, or NR^7R^7 , $\text{C}_3\text{-C}_{10}$ alkenyl, $\text{C}_3\text{-C}_{10}$ alkynyl, $\text{C}_3\text{-C}_6$ cycloalkyl, or $(\text{CH}_2)_{0-8}$ phenyl unsubstituted or substituted by one to three substituents selected from $\text{C}_1\text{-C}_6$ alkyl, nitro, Cl, Br, F, I, hydroxy, $\text{C}_1\text{-C}_6$ alkoxy, NR^7R^7 , CO_2R^7 , CN, or CONR^7R^7 ;

X is a single bond, S, or O;

30 R^3 is hydrogen, Cl, Br, F, I, CHO, hydroxymethyl, COOR^7 , CONR^7R^7 , NO_2 , or $\text{C}_n\text{F}_{2n+1}$;

each n is 1-3;

m is 0-4;

R^4 is CO_2R^7 , CONR^7R^7 , or tetrazol-5-yl;

Y is a single bond or a carbonyl group;

35 R^5 is hydrogen, $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl, $(\text{CH}_2)_{0-4}$ phenyl, or $(\text{CH}_2)_{0-3}$ CH-diphenyl wherein each

- 7 -


phenyl group independently is unsubstituted or substituted by one to three substituents selected from C_1 - C_6 alkyl, nitro, Cl, Br, F, I, hydroxy, C_1 - C_6 alkyl, NR^7R^7 , CO_2R^7 , or $CONR^7R^7$;

- 5 R^6 is hydrogen or C_1 - C_6 alkyl; and
each R^7 independently is hydrogen, C_1 - C_4 alkyl, or $(CH_2)_{0-4}$ phenyl; or a pharmaceutically acceptable salt thereof.

Preferred compounds included within the scope of
10 formula (VI) are 3-[(2-chlorophenyl)methyl]-2-propylthio-N-butrylhistidine and 3-[(2-chlorophenyl)-methyl]-2-n-butyl-N-butyrylhistidine; or a pharmaceutically acceptable salt thereof.

Compounds of formula (II) are prepared as
15 illustrated by Example 1.

Substituted imidazoles of the formula (III):



25 in which:

- R^1 is adamantylmethyl, or phenyl, biphenyl, or naphthyl, with each aryl group being unsubstituted or substituted by one to three substituents selected from
30 Cl, Br, F, I, C_1 - C_6 alkyl, nitro, CO_2R^8 , tetrazol-5-yl, C_1 - C_6 alkoxy, hydroxy, SC_1 - C_4 alkyl, SO_2NHR^8 , $NHSO_2R^8$, SO_3H , $CONR^8R^8$, CN, SO_2C_1 - C_4 alkyl, or C_nF_{2n+1} , wherein n is 1-3;
 R^2 is C_2 - C_{10} alkyl, C_3 - C_{10} alkenyl, C_3 - C_{10} alkynyl, C_3 - C_6 cycloalkyl, or $(CH_2)_{0-8}$ phenyl unsubstituted or
35 substituted by one to three substituents selected from C_1 - C_6 alkyl, nitro, Cl, Br, F, I, hydroxy, C_1 - C_6 alkoxy,

- 8 -

NR^8R^8 , CO_2R^8 , CN , or CONR^8R^8 ;

X is a single bond, S, or O;

R^3 is hydrogen, Cl, Br, F, I, CHO, hydroxymethyl,

CO_2R^8 , NO_2 , or $\text{C}_n\text{F}_{2n+1}$, wherein n is 1-3;

5 q is 0 to 4;

m is 0 to 2;

R^4 is H or C_{1-6} alkyl;

z is 0 to 1;

10 R^5 is C_{3-6} alkyl, C_{3-6} alkenyl, phenyl-Y-, 2- or 3-thienyl-Y-, 2- or 3-furyl-Y-, 2-, 3-, or 4-pyridyl-Y-, tetrazolyl-Y-, triazolyl-Y-, imidazolyl-Y-, pyrazolyl-Y-, thiazolyl-Y-, pyrrolyl-Y-, or oxazolyl-Y-, with each aryl ring being unsubstituted or substituted by C_{1-6} alkyl, Cl, Br, F, I, C_{1-6} alkoxy, NR^8R^8 , CO_2R^8 , or

15 CONR^8R^8 ;

Y is a single bond or C_{1-6} alkyl which is branched or unbranched;

R^6 is CO_2R^8 , CONR^8R^8 , or tetrazol-5-yl;

R^7 is H, CO_2R^8 , or C_{1-6} alkyl; and

20 each R^8 independently is hydrogen, C_{1-6} alkyl, or $(\text{CH}_3)_{0-4}$ phenyl; or a pharmaceutically acceptable salt thereof.

A preferred compound included within the scope of formula (VII) is 3-[2-n-butyl-1-((2-chlorophenyl)-methyl)-1H-imidazol-5-yl]-2-benzylpropanoic acid or a


25 pharmaceutically acceptable salt thereof.

Compounds of formula (III) are prepared as illustrated by Example 2.

30 Substituted imidazoles of the formula (IV) which are described in U.S. Application Serial No. 07/621,188, filed November 30, 1990:

35

- 9 -



in which:

5 R^1 is adamantylmethyl, or phenyl, biphenyl, or naphthyl, with each aryl group being unsubstituted or substituted by one to three substituents selected from Cl, Br, F, I, C_1 - C_6 alkyl, nitro, CO_2R^5 , C_1 - C_6 alkoxy, hydroxy, SC_1 - C_6 alkyl, SO_2C_1 - C_6 alkyl, tetrazol-5-yl, SO_2NHR^5 , $NHSO_2R^5$, SO_3H , $PO(OR^5)_2$, $CONR^5R^5$, CN, NR^5R^5 , NR^5COH , NR^5COC_1 - C_6 alkyl, $NR^5CON(R^5)_2$, NR^5COW , SO_2W , or W;

15 R^2 is C_2 - C_{10} alkyl, C_3 - C_{10} alkenyl, $(CH_2)_{0-8}$ - C_3 - C_6 cycloalkyl, or $(CH_2)_{0-8}$ phenyl unsubstituted or substituted by one to three substituents selected from C_1 - C_6 alkyl, nitro, Cl, Br, F, I, hydroxy, C_1 - C_6 alkoxy, tetrazol-5-yl, NR^5R^5 , CO_2R^5 , CN, $CONR^5R^5$, W, NR^5COH , NR^5COC_1 - C_6 alkyl, NR^5COW , SO_2W , SO_2C_1 - C_6 alkyl, or SC_1 - C_6 alkyl;

20 X is a single bond, S, NR^5 , or O;

n is 0-4;

R^3 is hydrogen, Cl, Br, F, I, CHO, hydroxymethyl, C_1 - C_6 alkyl, NR^5R^5 , CO_2R^5 , $CONR^5R^5$, NO_2 , CN, phenyl, or W;

25 R^4 is CO_2R^5 , $CONR^5R^5$, or tetrazol-5-yl;

30 Z is hydrogen, Cl, Br, F, I, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, CN, NO_2 , CO_2R^5 , COR^5R^5 , W, phenyl-Y-, naphthyl-Y-, thienyl-Y-, furyl-Y-, pyrazolyl-Y-, imidazolyl-Y-, thiazolyl-Y-, tetrazolyl-Y-, pyrrolyl-Y-, triazolyl-Y-, oxazolyl-Y-, or isoxazolyl-Y-, with each aryl or heteroaryl group being unsubstituted or substituted by C_1 - C_6 alkyl, C_1 - C_6 alkoxy, Cl, Br, F, I, CO_2R^5 , hydroxy, NO_2 , CN, $CONR^5R^5$, or W;

35 Y is a single bond or C_1 - C_6 alkyl, which is straight or branched;

W is C_mF_{2m+1} , wherein m is 1-4,; and

- 10 -

each R^5 independently is H or C_1 - C_6 alkyl;
or a pharmaceutically acceptable salt thereof.


A preferred compound included within the scope of
formula (IV) is 3-[2-n-butyl-1-[(2-chlorophenyl)-
5 methyl]-1H-imidazol-5-yl]benzoic acid or a
pharmaceutically acceptable salt thereof.

Compounds of formula (IV) are prepared as
illustrated by Example 3.

10

Substituted benzimidazoles of the formula (V):

15



(V)

20 in which:

R^1 is $-C(O)NH-CH(Y)-(CH_2)_n$ -aryl, $-C(O)NH-CH(Y)-$
(CH_2) $_n$ -heteroaryl, or phenyl unsubstituted or
substituted by one to three substituents selected from
Cl, Br, F, I, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, OH, CN, NO_2 , CO_2R^4 ,
25 tetrazol-5-yl, $CONR^4R^4$, SO_3H , C_mF_{2m+1} , SC_1 - C_6 alkyl, or
 SO_2C_1 - C_6 alkyl;

R^2 is hydrogen, C_2 - C_{10} alkyl, C_3 - C_{10} alkenyl, C_3 - C_6 -
cycloalkyl, C_mF_{2m+1} , or (CH_2) $_0$ -8phenyl unsubstituted or
substituted by one to three substituents selected from
30 C_1 - C_6 alkyl, C_1 - C_6 alkoxy, Cl, Br, F, I, OH, NO_2 , C_mF_{2m+1} ,
 CO_2R^4 , or NR^4R^4 ;

R^3 is $-(CH_2)_n$ -Y, $-CH=CY-(CH_2)_n$ -aryl, $-CH=CY-(CH_2)_n$ -
heteroaryl, $-(CH_2)_n$ - $C(O)-NH-CH(Y)-(CH_2)_n$ -aryl, $-(CH_2)_n$ -
 $C(O)-NH-CH(Y)-(CH_2)_n$ -heteroaryl, $-(CH_2)_m$ - $NH-CH(Y)-(CH_2)_n$ -
35 aryl or $-(CH_2)_m$ - $NH-CH(Y)-(CH_2)_n$ -heteroaryl, when R^1 is
an optionally substituted phenyl group; or H when R^1 is

- 11 -

-C(O)NH-CH(Y)-(CH₂)_n-aryl or -C(O)NH-CH(Y)-(CH₂)_n-heteroaryl;

Y is CO₂R⁴ or tetrazol-5-yl;

X is Cl, Br, F, I, C_mF_{2m+1}, C₁₋₆alkyl, C₁₋₆alkoxy, OH, O-phenyl, CO₂R⁴, tetrazol-5-yl, CN, or (CH₂)₀₋₄phenyl unsubstituted or substituted by Cl, Br, F, I, C₁₋₆alkyl, C₁₋₆alkoxy, OH, C_mF_{2m+1}, CN, CO₂R⁴, NO₂, or NR⁴R⁴;

aryl is phenyl, biphenyl, or naphthyl wherein each aryl group is unsubstituted or substituted by C₁₋₆alkyl, C₁₋₆alkoxy, Cl, Br, F, I, OH, NO₂, CF₃, CO₂R⁴, or NR⁴R⁴;

heteroaryl is 2- or 3-thienyl, 2-, or 3-furanyl, 2-, 3-, or 4-pyridyl, pyrimidyl, imidazolyl, thiazolyl, triazolyl, or tetrazolyl wherein each heteroaryl group is unsubstituted or substituted by C₁₋₆alkyl, C₁₋₆alkoxy, Cl, Br, F, I, OH, NO₂, CF₃, CO₂R⁴, or NR⁴R⁴;

each m independently is 1-3;

each n independently is 0-2; and

each R⁴ independently is H or C₁₋₆alkyl; or a pharmaceutically acceptable salt thereof.

A preferred compound included within the scope of formula (V) is 2-n-butyl-1-(4-carboxyphenyl)methyl-5-chloro-1H-benzimidazole-7-carboxylic acid or a pharmaceutically acceptable salt thereof.

Compounds of formula (V) are prepared following the methods described in Patent Cooperation Treaty Publication Number WO 91/16313, published October 31, 1991. Formula (V) compounds are prepared as illustrated by Example 4.

The above descriptions on pages 2-11 of classes of AII receptor antagonists for use in the present invention were taken from the noted patent applications and publications. Reference should be made to such patent applications and publications for their full

- 12 -

disclosure, the entire disclosure of each of which is incorporated herein by reference.

The following angiotensin II receptor antagonists are also included within the scope of the instant invention. Since it is contemplated that any AII receptor antagonist will possess the novel utility herein described, the list below does not limit the scope of the present invention.

| | Reference Citing AII Receptor |
|--|-------------------------------------|
| <u>AII Analog*</u> | <u>Blocking Activity</u> |
| Sar ¹ Ala ⁸ | Clin. Sci. 57: 71, 1979 |
| Sar ¹ Ile ⁸ | Endocrinology 107(5): 1365, 1980 |
| Succ ¹ Val ⁵ Phenylgly ⁸ | Clin. Sci. Mol. Med. 51: 4305, 1976 |
| desAsp ¹ Ile ⁸ | Am. J. Physiol. 236(3): F252, 1976 |
| Sar ¹ Thr ⁸ | Clin. Sci. Mol. Med. 51: 3855, 1976 |
| Sar ¹ Cys-Me ⁸ | J. Cardiovasc. Pharm. 5: 1025, 1983 |
| Sar ¹ Tyr-Me ⁴ Gly ⁸ | Life Sci. 34: 317, 1983 |
| Ile ⁸ | Can J. Physiol Pharm. 57: 121, 1979 |
| Leu ⁸ | Can J. Physiol Pharm. 57: 121, 1979 |
| Sar ¹ Leu ⁸ | Can J. Physiol Pharm. 57: 121, 1979 |
| desAsp ¹ Leu ⁸ | Can J. Physiol Pharm. 57: 121, 1979 |
| Sar ¹ Me-Ala ⁷ Ile ⁸ | Can J. Physiol Pharm. 57: 763, 1979 |
| Sar ¹ DL-Nipecotamide ⁷ Ile ⁸ | Can J. Physiol Pharm. 57: 763, 1979 |

- 13 -

| | | |
|----|--|---|
| | Sar ¹ Sar ⁷ Ile ⁸ | Can J. Physiol Pharm. <u>57</u> : 763, 1979 |
| | 8-L-Ala | J. Pharm. Pharmacol. <u>32</u> : 232, 1980 |
| 5 | Met ⁸ | J. Med. Chem. <u>22(9)</u> : 1147, 1979 |
| | Thr ⁸ | J. Med. Chem. <u>22(9)</u> : 1147, 1979 |
| | O-Me Thr ⁸ | J. Med. Chem. <u>22(9)</u> : 1147, 1979 |
| | N-Me Ile ⁸ | J. Med. Chem. <u>22(9)</u> : 1147, 1979 |
| | N-Me Phe ⁸ | J. Med. Chem. <u>22(9)</u> : 1147, 1979 |
| 10 | Sar ¹ Sar ⁷ Leu ⁸ | J. Med. Chem. <u>22(9)</u> : 1147, 1979 |
| | Sar ¹ Sar ⁷ Thr(Me) ^R | J. Med. Chem. <u>22(9)</u> : 1147, 1979 |
| | Sar ¹ Sar ⁷ DLaIle ⁸ | J. Med. Chem. <u>22(9)</u> : 1147, 1979 |
| | MeIle ¹ Thr ⁸ | J. Med. Chem. <u>20(2)</u> : 253, 1977 |
| | Me ₂ Gly ¹ Thr ⁸ | J. Med. Chem. <u>20(2)</u> : 253, 1977 |
| 15 | GdnAC ¹ Thr ⁸ | J. Med. Chem. <u>20(2)</u> : 253, 1977 |
| | desAsp ¹ Thr ⁸ | J. Med. Chem. <u>20(2)</u> : 253, 1977 |
| | Sar ¹ Ser(Me) ⁸ | J. Med. Chem. <u>20(2)</u> : 253, 1977 |
| | Sar ¹ Thr ⁸ | J. Med. Chem. <u>20(2)</u> : 253, 1977 |
| | Sar ¹ Thr(Me) ⁸ | J. Med. Chem. <u>19(2)</u> : 244, 1976 |
| 20 | MeAspNH ₂ ¹ Ile ⁸ | J. Med. Chem. <u>19(2)</u> : 244, 1976 |
| | Sar ¹ MeTyr ⁴ Ile ⁸ | J. Med. Chem. <u>19(2)</u> : 244, 1976 |
| | Sar ¹ MeIle ⁵ Ile ⁸ | J. Med. Chem. <u>19(2)</u> : 244, 1976 |
| | Sar ¹ MeIle ⁸ | J. Med. Chem. <u>19(2)</u> : 244, 1976 |
| | Sar ¹ MeIle ⁵ MeIle ⁸ | J. Med. Chem. <u>19(2)</u> : 244, 1976 |
| 25 | Sar ¹ Thr (O-/-Me) ⁸ | J. Med. Chem. <u>19(2)</u> : 244, 1976 |
| | Sar ¹ Met ⁸ | J. Med. Chem. <u>19(2)</u> : 244, 1976 |
| | Sar ¹ Ser ⁸ | J. Med. Chem. <u>19(2)</u> : 244, 1976 |
| | Ile ⁵ Ala ⁸ | J. Med. Chem. <u>13</u> : 181, 1970 |
| | Ile ⁵ , 8-(3-amino-4-phenyl)butyric acid | J. Med. Chem. <u>13</u> : 181, 1970 |
| 30 | Asn ¹ Ala ⁸ | Circ. Res. <u>29</u> : 664, 1971 |
| | Sar ¹ Cys(Me) ⁸ | Circ. Res. <u>46</u> : 720, 1980 |
| | Phe ⁴ Tyr ⁸ | Proc. Nat Acad. Sci. <u>67</u> :1624, 1970 |
| 35 | OctanoylLeu ⁸ | J. Med. Chem. <u>20</u> : 898, 1977 |
| | Cys ⁸ | Cir. Res. <u>31</u> : 862, 1972 |

SUBSTITUTE SHEET

- 14 -

| | |
|---|---------------------------------|
| Phe ⁴ Tyr ⁸ | Cir. Res. <u>31</u> : 862, 1972 |
| desAsp ¹ Phe ⁴ Tyr ⁸ | Cir. Res. <u>31</u> : 862, 1972 |
| para-fluoroPhe ⁴ | Cir. Res. <u>31</u> : 862, 1972 |
| para-fluoroPhe ⁸ | Cir. Res. <u>31</u> : 862, 1972 |

5

*Abbreviations indicate substitutions in the Angiotensin II sequence Asp-Arg-Val-Tyr-Ile-His-Pro-Phe with the location of the substitution identified by the superscript.

10

Other classes of AII receptor antagonists are disclosed in the following:

15 Sipos et al., U.S. Patent No. 3,751,404, issued August 7, 1973. A particularly preferred compound in this class of AII receptor antagonists is Sar-Arg-Val-Tyr-Val-His-Pro-β-Ala-OH which is also referred to as Saralasin.

20 Regoli et al., U.S. Patent No. 3,907,762, issued September 23, 1975. Examples of suitable compounds within this class are Asp-Arg-Val-Tyr-Ile-His-Pro-Val-OH and Asp-Arg-Val-Tyr-Ile-His-Pro-α-amino-n-butyric acid.

25 Nyeki et al., U.S. Patent No. 4,388,304, issued June 14, 1983. Compounds disclosed in this patent include Sar-Arg-Val-Tyr-Ile-His-Pro-Ile-methyl ester and hydroxyacetyl-Arg-Val-Tyr-Ile-His-Pro-Thr-methyl ester. The same or similar compounds are also disclosed in European Patent No. 34,259.

30 Sipos et al., U.S. Patent No. 3,886,134 issued May 27, 1975. Examples of compounds of this class are Sar-Arg-Val-Tyr-Val-His-Pro-Ala-OH, Ser-Arg-Val-Tyr-Val-His-Pro-Ala-OH, and Asn-Arg-Val-Tyr-Val-His-Pro-D-Leu-OH.

35 Kisfaludy et al., U.S. Patent No. 4,179,433, issued December 18, 1979. Examples of this class of compounds include aminooxyacetyl-Arg-Val-Tyr-Ile-His-Pro-Leu-OH and D-α-aminoxypionyl-Arg-Val-Tyr-Ile-His-Pro-Leu-

OH.

Hallinan et al., U.S. Patent No. 4,204,991, issued May 27, 1980. See also West German Offenlegungsschrift No. 2846200 (Chemical Abstracts, Vol. 91, Abstract No. 5 74989d).

Kisfaludy et al., U.S. Patent No. 4,209,442, issued June 24, 1980. Examples include hydroxyacetyl-Arg-Val-Tyr-Ile-His-Pro-Leu-OH, hydroxyacetyl-Arg-Val-Tyr-Ile-His-Pro-Ala-OH, and α -hydroxypropionyl-Arg-Val-Tyr-Ile-10 His-Pro-Ile-OH.

Nyeki et al., U.S. Patent No. 4,330,532, issued May 18, 1982. Exemplary compounds of this class are Sar-Arg-Val-Tyr-Ile-His-Pro-Lac, Sar-Arg-Val-Tyr-Ile-His-Pro-Lac(OC₂H₅), and Sar-Arg-Val-Tyr-Ile-His-Pro-2-15 hydroxy-3-methylvaleric acid.

Furukawa et al., U.S. Patent No. 4,340,598 issued June 20, 1982. Examples include 1-benzyl-4-chloro-2-phenylimidazole-5-acetamide, 1-benzyl-2-n-butyl-4-chloroimidazole-5-acetamide, and 1-benzyl-2-n-butyl-5-20 chloroimidazole-4-acetic acid.

Furukawa et al., U.S. Patent No. 4,355,040, issued October 19, 1982. Examples include 1-(2-chlorobenzyl)-2-n-butyl-4-chloroimidazole-5-acetic acid and 1-benzyl-4-chloro-2-(4-chloro-3,5-dinitrophenyl)imidazole-5-25 acetic acid.

Furukawa, et al., in European Patent Publication No. 103 647, published March 28, 1984. A preferred compound included within the scope of this class of AII receptor antagonists is 4-chloro-1-(4-hydroxy-3-30 methylbenzyl)-2-phenylimidazole-5-acetic acid or a pharmaceutically acceptable salt thereof.

Carini et al., in European Patent Publication No. 253 310, published January 20, 1988 and U.S. Application Serial No. 50341 filed May 22, 1987. 35 Preferred compounds included within this class of AII receptor antagonists are 2-n-butyl-4-chloro-1-[(2'-(1H-

- 16 -

tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole and 2-n-butyl-4-chloro-1-[(2'-(carboxybiphenyl-4-yl)methyl]-5-(hydroxymethyl)-imidazole; or a pharmaceutically acceptable salt thereof.

Blankley et al., in European Patent Publication No. 245 637, published November 19, 1987 and U.S. Application Serial No. 847067, filed April 1, 1986. Preferred compounds included within the scope of this class of AII receptor antagonists are 1-(2-phenylethyl)-5-phenylacetyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid and 1-(4-amino-3-methylphenyl)methyl-5-diphenylacetyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid; or a pharmaceutically acceptable salt thereof.

Carini et al., in European Patent Publication No. 323 841, published July 12, 1989 and U.S. Application No. 07/279,193, filed December 6, 1988. Preferred compounds included in this class of AII receptor antagonists are 5-n-propyl-1-[(2'-(carboxybiphenyl-4-yl)methyl]pyrrole-2-carboxylic acid, 3-methoxymethyl-5-n-propyl-4-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-1,2,4-triazole, and 3-methoxymethyl-5-n-butyl-1-[2'-(carboxybiphenyl-4-yl)methyl]pyrazole; or a pharmaceutically acceptable salt thereof.

Carini, et al., U.S. Patent No. 4,880,804, issued November 14, 1989. Preferred compounds included within this class of AII receptor antagonists are 2-n-butyl-1-[(2'-(carboxybiphenyl-4-yl)methyl]-5-hydroxymethylbenzimidazole and 2-n-butyl-1-[(2'-(carboxybiphenyl-4-yl)methyl]-6-hydroxymethylbenzimidazole; or a pharmaceutically acceptable salt thereof.

Carini, et al., U.S. Patent No. 4,916,129, issued April 10, 1990. A preferred compound included within this class of AII receptor antagonists is 5-[4-(3-(N-

- 17 -

iso-propylamino)hydroxypropoxy)indole-2-carboxamidomethyl]-2-n-butyl-1-[(2'-carboxybiphenyl-4-yl)methyl]-4-chloroimidazole or a pharmaceutically acceptable salt thereof.

5 Rosenberg, et al., U.S. Patent No. 4,857,507, issued August 15, 1989. Examples include Boc-Phe-Leu amide of (4S)-3-oxo-4-amino-2,2-difluoro-1-isopropyl-mercapto-5-cyclohexylpentane and Boc-Phe-Leu amide of
10 (3R,4S,EZ)-3-hydroxy-4-amino-2-fluoro-1-isopropyl-sulfonyl-5-cyclohexyl-1-pentene; or a pharmaceutically acceptable salt thereof.

Wissmann et al. U.S. Patent No. 4,013,791, issued March 22, 1977. An example of such compounds is succinamoyl-Arg-Val-Tyr-Val-His-Pro-Phegly-OH where
15 Phegly-OH is a L-C-phenylglycine residue.

Bumpus et al., U.S. Patent No. 3,923,769, issued December 2, 1975.

Bumpus et al., U.S. Patent No. 3,923,770, issued December 2, 1975.

20 Bumpus et al. U.S. Patent No. 3,923,771, issued December 2, 1975.

Bumpus et al., U.S. Patent No. 3,925,345, issued December 9, 1975.

Bumpus et al., U.S. Patent No. 3,976,770, issued
25 August 24, 1976.

Wille U.S. Patent No. 3,915,948, issued October 28, 1975. An example of an AII receptor antagonist included in this reference is Sar-Arg- Val-Tyr-Val-His-Pro-OH

Lifer, et al., European Patent Publication Number
30 EP 0 438 869, published July 31, 1991 and U.S. Application Serial No. 07/444,456, filed November 30, 1989. A preferred compound of this class of AII receptor antagonists is α -hexyl-4-[(2-carboxy-3-hydroxybenzoyl)amino]-1H-imidazole-1-acetic acid ethyl
35 ester or a pharmaceutically acceptable salt or solvate thereof.

SUBSTITUTE SHEET

- 18 -

Chakravarty, et al., European Patent Publication Number EP 0 401 030, published December 5, 1990 and U.S. Application Serial No. 07/522,662, filed May 16, 1990. A preferred embodiment of this class of AII receptor
5 antagonists includes 2-n-butyl-3-(2'-tetrazol-5-yl)biphenyl-4-yl)methyl-6,7-dihydroimidazo[4,5-e][1,4]diazepine-8(3H)-one or a pharmaceutically acceptable salt thereof.

Chakravarty, et al., European Patent Publication
10 Number EP 0 400 974, published December 5, 1990 and U.S. Application Serial No. 07/516,286, filed May 4, 1990. An example included within the scope of this class of AII receptor antagonists is 5,7-dimethyl-2-ethyl-3-(2'-(tetrazol-5-yl)biphenyl-4-yl)methyl-3H-imidazo[4,5-
15 b]pyridine or a pharmaceutically acceptable salt thereof.

Chakravarty, et al., European Patent Publication Number EP 0 400 835, published December 5, 1990 and U.S. Application Serial No. 07/504,441, filed April 4, 1990.
20 A preferred embodiment of this class of AII receptor antagonists includes 4,6-dimethyl-2-ethyl-1-[2-(tetrazol-5-yl)biphenyl-4-yl]methylbenzimidazole or a pharmaceutically acceptable salt thereof.

Ashton, et al., European Patent Publication Number
25 EP 0 409 332, published January 23, 1991 and U.S. Application Serial No. 07/503,352, filed April 2, 1990. A preferred embodiment of this class of AII receptor antagonists includes 3-n-butyl-4-[4-(2-carboxybenzamido)benzyl]-5-(2-methylbenzylthio)-4,1,2,4-triazole
30 or a pharmaceutically acceptable salt thereof.

Greenlee, et al., European Patent Publication Number EP 0 407 102, published January 9, 1991 and U.S. Application Serial No. 07/516,502, filed April 25, 1990. A preferred embodiment of this class of AII receptor
35 antagonists includes 2-n-butyl-1,5-dihydro-4,5-dimethyl-1-[(2'-(1H-tetrazol-5-yl){1,1-biphenyl}-4-yl)methyl]-

- 19 -

pyrrolo[3,4-d]imidazole or a pharmaceutically acceptable salt thereof.

Carini, et al., European Patent Publication Number EP 0 324 377, published July 19, 1989 and U.S.

5 Application Serial No. 07/279,194, filed December 6, 1988. A preferred embodiment of this class of AII receptor antagonists includes 2-n-propyl-4-pentafluoroethyl-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid or a
10 pharmaceutically acceptable salt thereof.

Oku, et al., European Patent Publication Number EP 0 3426 021, published May 8, 1991. A preferred embodiment of this class of AII receptor antagonists includes 2-n-butyl-7-methyl-3-[(2-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-3H-imidazo[4,5-b]pyridine or a
15 pharmaceutically acceptable salt thereof.

Roberts, et al., European Patent Publication Number EP 0 412 848, published February 13, 1991. A preferred embodiment of this class of AII receptor antagonists includes 2-methyl-4-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methoxy]quinoline or a pharmaceutically acceptable salt thereof.

Roberts, et al., Patent Cooperation Treaty Application Publication Number WO 91/07404, published
25 May 30, 1991. A preferred embodiment of this class of AII receptor antagonists includes 2-ethyl-4-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methoxy-1,5-naphthyridine or a pharmaceutically acceptable salt thereof.

Roberts, et al., European Patent Publication Number
30 EP 0 399 732, published November 28, 1990. A preferred embodiment of this class of AII receptor antagonists includes 4-[(2-n-butyl-1H-benzimidazol-1-yl)methyl-N-phenylsulphonyl]benzamide or a pharmaceutically acceptable salt thereof.


35 Miyake, et al., European Patent Publication Number EP 0 420 237, published March 3, 1991. A preferred

- 20 -

embodiment of this class of AII receptor antagonists includes 7-methyl-2-n-propyl-3-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-3H-imidazo[4,5-b] or a pharmaceutically acceptable salt thereof.

5 Narr, et al., European Patent Publication Number EP 0 392 317, published November 17, 1990. A preferred embodiment of this class of AII receptor antagonists includes 4'-[(6-n-butanoylamino-2-n-butyl-benzimidazol-1-yl)methyl]biphenyl-2-carboxylic acid or a
10 pharmaceutically acceptable salt thereof.

 An angiotensin II receptor antagonist of the formula (VI):



 which is 2-n-butyl-4-chloro-1-([3-bromo-2-[2-(tetrazol-5-yl)phenyl]benzofuranyl-4-yl]methyl)imidazole-5-acetic
20 acid or a pharmaceutically acceptable salt thereof.

 The above descriptions of classes of AII antagonists for use in the present invention were taken from pending patent applications, noted patents, and publications or from abstracts thereof. Reference
25 should be made to such patents and publications themselves for their full disclosures of such classes and specific compounds within such classes, the entire disclosure of such patents and publications being incorporated herein by reference. Furthermore, examples
30 1-4 teach how to make compounds encompassed by the generic Formulae of (II)-(V).

 Many AII antagonists are known in the art and may be prepared by known methods or by variations thereof. Certain AII antagonists employed in the invention may
35 exist in isomeric form. This invention includes all such isomers both in pure form and admixture, including

- 21 -

racemic mixtures and their pharmaceutically acceptable salts.

Angiotensin II antagonist activity is assessed by in vitro methods. In vitro antagonist activity is
5 determined by the ability of the compounds to compete with ^{125}I -angiotensin II for binding to vascular angiotensin II receptors and by their ability to antagonize the contractile response to angiotensin II in the isolated rabbit aorta. For the purposes of the
10 present invention the preferred AII antagonists are compounds which are capable of inhibiting the action of AII by at least 50% at a concentration of 1mM or less, and especially preferred AII antagonists are compounds which are capable of inhibiting the action of AII by at
15 least 50% at a concentration of 25nM or less when tested by the following standard methods.

Binding

The radioligand binding assay is a modification of
20 a method previously described in detail (Gunther et al., Circ. Res. 47:278, 1980). A particular fraction from rat mesenteric arteries is incubated in Tris buffer with 80 pM of ^{125}I -angiotensin II with or without angiotensin II antagonists for 1 hour at 25°C. The incubation is
25 terminated by rapid filtration and receptor bound ^{125}I -angiotensin II trapped on the filter is quantitated with a gamma counter. The potency of angiotensin II antagonists is expressed as the IC_{50} which is the concentration of antagonist needed to displace 50% of
30 the total specifically bound angiotensin II.

Aorta

The ability of the compounds to antagonize angiotensin II induced vasoconstriction is examined in
35 the rabbit aorta. Ring segments are cut from the rabbit thoracic aorta and suspended in organ baths containing

SUBSTITUTE SHEET

- 22 -

physiological salt solution. The ring segments are mounted over metal supports and attached to force displacement transducers which are connected to a recorder. Cumulative concentration response curves to
5 angiotensin II are performed in the absence of antagonist or following a 30-minute incubation with antagonist. Antagonist dissociation constants (K_B) are calculated by the dose ratio method using the mean effective concentrations.

10 In the therapeutic use for the treatment of diabetic nephropathy the AII receptor antagonizing compounds of this invention are incorporated into standard pharmaceutical compositions. They can be administered orally, parenterally, rectally, topically
15 or transdermally.

The compounds of the instant invention and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids, for example
20 syrups, suspensions or emulsions, tablets, capsules and lozenges.

A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid
25 carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example, polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.

A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s)
30 routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.

A composition in the form of a capsule can be prepared using routine encapsulation procedures. For
35 example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a

- 23 -

hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or
5 suspension then filled into a soft gelatin capsule.

The compounds of the instant invention and their pharmaceutically acceptable salts which are active when administered parenterally (i.e. by injection of infusion) can be formulated as solutions or suspensions.

10 A composition for parenteral administration will generally consist of a solution or suspension of the active ingredient in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or
15 sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.

A typical suppository composition comprises a compound of the instant invention or a pharmaceutically
20 acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent such as polymeric glycols, gelatins or coca butter or other low melting vegetable or synthetic waxes or fats.

25 A typical transdermal formulation comprises a conventional aqueous or non-aqueous vehicle, for example, a cream, ointment lotion or paste or in the form of a medicated plaster, patch or membrane.

For topical administration, the pharmaceutical
30 compositions adapted include solutions, suspensions, ointments, and solid inserts. Typical pharmaceutically acceptable carriers are, for example, water, mixtures of water and water-miscible solvents such as lower alkanols or vegetable oils, and water soluble ophthalmologically
35 acceptable non-toxic polymers, for example, cellulose derivatives such as methyl cellulose. The

SUBSTITUTE SHEET

- 24 -

pharmaceutical preparation may also contain non-toxic auxiliary substances such as emulsifying, preserving, wetting, and bodying agents, as for example, polyethylene glycols; antibacterial components such as quaternary ammonium compounds; buffering ingredients such as alkali metal chloride; antioxidants such as sodium metabisulfite; and other conventional ingredients such as sorbitan monolaurate.

Preferably the composition is in unit dose form.

10 Doses of the compounds of the instant invention in a pharmaceutical dosage unit will be an efficacious, non-toxic quantity selected from the range of .01 - 200 mg/kg of active compound, preferably .1 - 100 mg/kg. The selected dose is administered to a human patient in

15 need of treatment of diabetic nephropathy induced by angiotensin II from 1-6 times daily, orally, rectally, topically, by injection, or continuously by infusion. Oral dosage units for human administration preferably contain from 10 to 500 mg of active compound. Lower

20 dosages are used generally for parenteral administration. Oral administration is used when safe, effective, and convenient for the patient.

No unacceptable toxicological effects are expected when compounds of the invention are administered in

25 accordance with the present invention.

The following examples are intended to illustrate, but not to limit, the present invention. Examples 1-4 describe how to make certain compounds encompassed by the generic formulae of (II)-(V). The remaining

30 examples are directed to pharmaceutical compositions of this invention. The compounds included in these disclosed compositions are representative of the AII receptor antagonists included within the scope of the instant invention, but therapeutically effective amounts

35 of other AII antagonists as discussed hereinabove may be substituted.

- 25 -

The procedures of Examples 1-4 are illustrative of the synthesis of compounds encompassed by generic formulae (II)-(V). Substitution of starting materials by the appropriate known reagents yields additional

5 compounds within the scope of formulae (II)-(V).

Reagents, protecting groups, and functionality on the imidazole and other fragments of the molecule must be consistent with the proposed chemical transformations.

The procedure of Example 1 is illustrative of the
10 synthesis of compounds encompassed by generic formula (II).

Example 1

3-[(2-Chlorophenyl)methyl]-2-propylthio-N-
butyrylhistidine

15 (i) 5-carboxymethyl-1-(2-chlorophenyl)methyl-2-thio-1H-imidazole

A solution of 2-chlorobenzylamine (14.2 g, 0.1 mol) and triethylamine (13.9 mL, 0.1 mol) in dimethylformamide (100 mL) was treated with methyl chloroacetate
20 (10.9 g, 0.1 mol). The mixture was heated at 50°C for 3.5 hours. The cooled reaction mixture was diluted with diethyl ether, the solids filtered and the concentrated filtrate was flash chromatographed over silica gel with 6:4 hexane in ethyl acetate to provide 15.3 g (71%) of
25 homogenous methyl 2-[N-(2-chloro-phenyl)methyl]aminoacetate. This product (15.2 g, 0.071 mol) in xylene (100 mL) was treated with 98% formic acid (2.74 mL, 0.0711 mol) and the mixture was refluxed for 2.5 hours with a Dean-Stark water separator. Evaporation gave
30 17.1 g (99%) of methyl 2-[N-(2-chlorophenyl)methyl-N-formyl] aminoacetate. This formylated product (17.0 g, 0.071 mol) was dissolved in methyl formate (13.3 mL, 0.216 mol) and added dropwise to a sodium methoxide mixture prepared by adding sodium metal (1.79 g, 0.0778
35 g-atom) to tetrahydrofuran (325 mL) followed by slow addition of methanol (3.15 mL, 0.0778 mol). The

SUBSTITUTE SHEET

- 26 -

combined mixture was stirred at room temperature for 18 hours, then evaporated to dryness. This crude product was dissolved in 50% aqueous methanol (200 mL), treated with charcoal, filtered and the solution was cooled in ice. Concentrated hydrochloric acid (14.3 mL of 12 N, 0.171 mol) was added slowly to this solution followed by a solution of potassium thiocyanate (8.6 g, 0.0885 mol) in water (20mL). The mixture was heated in an oil bath held at 90°C for 2.5 hours, then cooled to -10°C. The precipitated solid was filtered, washed with cold ethanol-water and dried at 60°C to provide 14.7 g (74%) of 5-carboxymethyl-1-(2-chlorophenyl)methyl-2-thio-1H-imidazole; m.p. 72-74°C.

(ii) 1-(2-chlorophenyl)methyl-5-chloromethyl-2-propylthio-1H-imidazole

A mixture of 5-carboxymethyl-1-(2-chlorophenyl)-methyl-2-thio-1H-imidazole (2 g, 7.08 mmol), ethyl acetate (20 mL), 5% sodium carbonate solution (40 mL) and propylbromide (4 mL, 44 mmol) was heated at 60°C for 18 hours. The organic layer was separated, dried over magnesium sulfate and concentrated to 2.23 g of crude product. Trituration with diethyl ether provided 1.63 g (71%) of 5-carboxymethyl-1-(2-chlorophenyl)methyl-2-propylthio-1H-imidazole; m.p. 68-71°C (from hexane).

The ester was hydrolyzed with aqueous sodium hydroxide solution to give 1-(2-chlorophenyl)methyl-2-thiopropyl-1H-imidazole-5-carboxylic acid; m.p. 158-159.5°C (from ethanol).

A solution of 5-carboxymethyl-1-(2-chlorophenyl)methyl-2-propylthio-1H-imidazole (3.74 g, 11.5 mmol) in dry tetrahydrofuran (50 mL) was cooled to -78°C under argon, and a solution of diisobutyl aluminum hydride in toluene (30 mL of 1 M) was added dropwise. The mixture was stirred at -78°C for 1.5 hours, then allowed to slowly warm to room temperature. The reaction was quenched by pouring onto iced dilute acetic

- 27 -

acid, the product was extracted into methylene chloride and the organic extracts were washed with water, 5% sodium carbonate solution and brine. The dried, concentrated product was a light tan solid (3.32 g).

- 5 Crystallization from ethanol/water gave 1-(2-chlorophenyl)methyl-5-hydroxymethyl-2-propylthio-1H-imidazole; m.p. 98-101°C.

A mixture of 1-(2-chlorophenyl)methyl-5-hydroxymethyl-2-propylthio-1H-imidazole (0.117 g, 0.393 mmol) in thionyl chloride (1 mL) was refluxed for 2 hours, evaporated in vacuo to an amorphous solid and triturated with ether to provide 1-(2-chlorophenyl)-methyl-5-chloromethyl-2-propylthio-1H-imidazole hydrochloride (0.13 g, 94%).

- 15 (iii) 3-[(2-chlorophenyl)methyl]-2-propylthio-histidine ethyl ester

A solution of diisopropylamine (8.4 mL) in tetrahydrofuran (100 mL) was cooled to -78°C under argon and a solution of n-butyl lithium (30 mL of 2.5 M in hexane) was added. The mixture was stirred at -78°C for 30 minutes and at 0°C for 10 minutes. After being recooled to -78°C, a solution of N-(diphenylmethylene)-glycine ethyl ester (Tetra. Lett., (1978), 2541, 4625) (15.4 g) in tetrahydrofuran (50 mL) was added, the mixture was stirred for 1 hour at -78°C and a solution of 1-(2-chlorophenyl)methyl-5-chloromethyl-2-propylthio-1H-imidazole hydrochloride (9.4 g) in dry dimethylformamide (20 mL) was added. The mixture was then stirred at ambient temperature for 18 hours, poured into saturated ammonium chloride solution and the aqueous layer was extracted with methylene chloride. The organic extracts were washed with water, dried with magnesium sulfate concentrated and chromatographed over silica gel with 1% methanol in methylene chloride to afford 6.88 g of 3-[(2-chlorophenyl)methyl]-2-propylthio-N-(diphenylmethylene)histidine ethyl ester.

SUBSTITUTE SHEET

- 28 -

This product (2.59 g) was dissolved in methylene chloride (52 mL), aqueous 1N hydrochloric acid solution (52 mL) was added and the mixture was stirred at 25°C for 18 hours. The aqueous layer was separated,
5 neutralized to pH 10.5 with sodium carbonate and the product was extracted into methylene chloride. The organic extract was dried with magnesium sulfate and concentrated to give 1.29 g (71%) of 3-[(2-chlorophenyl)methyl]-2-propylthio-histidine ethyl ester
10 as an oil.

(iv) 3-[(2-chlorophenyl)methyl]-2-propylthio-N-butyrylhistidine ethyl ester

A solution of 3-(2-chlorophenyl)methyl-2-propylthiohistidine ethyl ester (0.4 g, 1.05 mmol) in
15 methylene chloride (20 mL) was treated with triethylamine (0.17 mL) and butyryl chloride (0.12 mL). The mixture was stirred at 25°C for 18 hours. The reaction was partitioned between ethyl acetate and water, and the organic layer was washed with water,
20 dried, concentrated and chromatographed over silica gel with 1 to 3% of methanol in methylene chloride to give 0.367 g (77%) of 3-[(2-chlorophenyl)methyl]-2-propylthio-N-butyrylhistidine ethyl ester as an oil.

(v) 3-(2-chlorobenzenemethyl)-2-propylthio-N-butyrylhistidine
25

A mixture of 3-[(2-chlorophenyl)methyl]-2-propylthio-N-butyrylhistidine ethyl ester (0.37 g, 0.819 mmole), ethanol (4 mL), water (4 mL) and potassium hydroxide pellets (0.098 g, 1.75 mmole) was stirred at
30 25°C for 1 hour. The reaction was then diluted with water and the pH was adjusted to 4 with 1N aqueous hydrochloric acid solution. The product was extracted into methylene chloride, washed with water, dried and concentrated to an orange solid. Two crystallizations
35 from chloroform provided 0.22 g of 3-[(2-chlorophenyl)methyl]-2-propylthio-N-butyrylhistidine;

- 29 -

m.p. 178°-181°C.

The procedure of Example 2 is illustrative of the synthesis of compounds encompassed by generic formula
5 (III).

Example 2

3-[2-n-Butyl-1-((2-chlorophenyl)methyl)-1H-imidazol-5-yl]-2-benzylpropanoic Acid

(i) 2-n-butyl-1-(2-chlorophenyl)methyl-1H-
10 imidazole

Imidazole was converted to the 1-diethoxyorthoamide derivative by the method of Curtis and Brown, J. Org. Chem., (1980), 45, 20. Imidazole (12.8 g, 0.19 mol) and 118.4 g (0.8 mol) of triethylorthoformate were
15 reacted in the presence of 1 g of p-toluenesulfonic acid to give 20.6 (61%), bp 65-70°C (0.1 mm) of 1-diethoxyorthoamide imidazole. This product (24.0 g, 0.14 mol) was dissolved in dry tetrahydrofuran (250 mL), cooled to -40°C and n-butyl lithium (0.14 mol, 56.4 mL
20 of 2.5 M in hexane) was added at -40°C to -35°C. After 15 minutes n-butyl iodide (31.1 g, 0.169 mol) was added at -40°C, and the reaction was stirred overnight at ambient temperature. The reaction was partitioned between ether and 0.3 N hydrochloric acid, and the
25 organic layer was repeatedly extracted with dilute hydrochloric acid. The combined aqueous extracts were neutralized with sodium bicarbonate solution, extracted with methylene chloride, dried over magnesium sulfate and concentrated. A flash distillation on a Kugelrohr
30 apparatus provided 14.8 g (85%) of 2-n-butylimidazole.

2-n-Butylimidazole (9.7 g, 0.078 mol) was dissolved in methanol (50 mL) and added dropwise to a solution of sodium methoxide (from sodium hydride (2.31 g, 0.0934 mol) in methanol (250 mL)). After one hour the solution
35 was evaporated to dryness, and the sodium salt was taken up in dry dimethylformamide (150 mL) and 2-chlorobenzyl

SUBSTITUTE SHEET

- 30 -

bromide (16.3 g, 0.079 mol) was added. The mixture was heated at 50°C for 17 hours under argon, poured onto ice water and the product was extracted into ethyl acetate. The extract was washed, dried, and concentrated to give
5 18.5 g of crude product which was chromatographed over silica gel with 2:1 ethyl acetate/hexane to provide 11.9 g (61%) of 2-n-butyl-1-(2-chlorophenyl)methyl-1H-imidazole as an oil. Thin layer chromatography on silica gel with 4:1 ethyl acetate/hexane gave an R_f
10 value of 0.59.

(ii) 2-n-butyl-1-(2-chlorophenyl)methyl-5-hydroxymethyl-1H-imidazole

Method 1

A mixture of 2-n-butyl-1-(2-chlorophenyl)methyl-1H-imidazole (95.5 g, 0.384 mol), 37% formaldehyde (500
15 mL), sodium acetate (80 g) and acetic acid (60 mL) was heated to reflux for 40 hours under argon. The reaction was concentrated in vacuo, and the residue was stirred with 500 mL of 20% sodium hydroxide solution for 4
20 hours, diluted with water and extracted with methylene chloride. The extract was washed, dried, and concentrated. The crude product (117 g) was flash chromatographed over 600 g of silica gel with a gradient of ethyl acetate to 10% of methanol in ethyl acetate to
25 give 8.3 g of starting material, 24.5 g of a mixture of starting material and product, and 44 g (41%) of 2-n-butyl-1-(2-chlorophenyl)methyl-5-hydroxymethyl-1H-imidazole; mp 86-88°C (from ethyl acetate). Further elution provided the bis (4,5-hydroxymethyl) derivative;
30 mp 138-140°C (from ethyl acetate).

Method 2

A mixture of valeramidine methyl ether hydrochloride (250 g, 1.66 mol) and dihydroxyacetone (150 g, 0.83 mol) dissolved in liquid ammonia was
35 allowed to stand overnight at room temperature in a pressure vessel, and then heated at 65°C for 4 hours at

- 31 -

375 psi. The ammonia was allowed to evaporate, and the residue was dissolved in methanol (3L). The resulting slurry was refluxed with added acetonitrile (1L). The solution was decanted from the solid ammonium chloride while hot. This procedure was repeated, and the combined acetonitrile extracts were treated with charcoal, filtered hot and the filtrate was concentrated in vacuum to give the dark oil, 2-n-butyl-5-hydroxymethylimidazole (253 g, 1.63 mol, 98%).

10 This crude alcohol (253 g) was treated with acetic anhydride (400 mL) at -15°C and then was allowed to warm to ambient temperature with stirring, and then stirred an additional 19 hours. The acetic anhydride was evaporated at reduced pressure, the residue taken up in 15 methylene chloride, and the organic phase was washed with 5% sodium bicarbonate solution and water. The extract was dried over sodium sulfate and concentrated to give 323 g (83%) of 1-acetyl-4-acetoxymethyl-2-n-butylimidazole.

20 This diacetate was N-alkylated by the following procedure. To a solution of triflic anhydride (120 mL, 0.71 mol) in methylene chloride (200 mL) at -78°C under argon was added a solution of diisopropyl ethylamine (128 mL, 0.73 mol) and 2-chlorobenzyl alcohol (104 g, 25 0.72 mol) in methylene chloride (350 mL) over a period of 20 minutes. After being stirred an additional 20 minutes at -78°C, this solution was then treated with 1-acetyl-4-acetoxymethyl-2-n-butylimidazole (146 g, 0.61 mol) dissolved in methylene chloride (300 mL) over a 20- 30 minute interval. The mixture was then stirred at ambient temperature for 18 hours and the solvents were evaporated, The residual 2-n-butyl-5-acetoxymethyl-1-(2-chlorophenyl)methyl-1H-imidazole was used without purification for the hydrolysis of the acetate group.

35 A solution of crude 2-n-butyl-5-acetoxymethyl-1-(2-chlorophenyl)methyl-1H-imidazole (250 g) in methanol

SUBSTITUTE SHEET

- 32 -

(200 mL) was treated with 10% sodium hydroxide solution (700 mL) and the mixture was heated on a steam bath for 4 hours. After cooling, methylene chloride was added, the organic phase was separated, washed with water, dried and concentrated. The residue was dissolved in ether, cooled, and seeded to give the crude product. Recrystallization from ethyl acetate gave 176 g of 2-n-butyl-1-(2-chlorophenyl)methyl-5-hydroxymethyl-1H-imidazole; mp 86-88°C. This material was identical in all respects to the product prepared by Method 1.

(iii) 2-n-butyl-2-(2-chlorophenyl)methyl-5-chloromethyl-1H-imidazole

A mixture of 2-n-butyl-1-(2-chlorophenyl)methyl-5-hydroxymethyl-1H-imidazole, prepared in Example 1(ii), (10 g, 0.0337 mol) in thionyl chloride (75 ml) was refluxed for one hour, evaporated *in vacuo* and the residue azeotroped three times with toluene. The solid was triturated with ethyl ether and collected to provide 10.4 g (88%) of the hydrochloride salt of 2-n-butyl-1-(2-chlorophenyl)methyl-5-chloromethyl-1H-imidazole.

(iv) diethyl [2-n-butyl-1-[(2-chlorophenyl)methyl]-1H-imidazol-5-yl]-2-benzylmalonate

To dry dimethylformamide (50 mL) under argon was added sodium hydride (0.53 g, 0.022 mol) followed by diethyl benzyl malonate (5.51 g, 0.022 mol) in dimethylformamide (10 mL) at 0°C. The mixture was stirred at ambient temperature for one hour. A solution of 2-n-butyl-1-(2-chlorophenyl)methyl-5-chloromethyl-1H-imidazole hydrochloride (3.5 g, 0.0105 mol) in dimethylformamide (40 mL) was added over 5 minutes. The reaction mixture was stirred at 25°C for 18 hours, then partitioned between water and methylene chloride. The organic layer was washed with water, dried, and concentrated. The crude product was flash chromatographed over silica gel to give 4.54 g (85%) of the title compound as an oil.

- 33 -

(v) 3-[2-n-butyl-1-((2-chlorophenyl)methyl)-1H-imidazol-5-yl]-2-benzylpropanoic acid

A mixture of diethyl [2-n-butyl-1-((2-chlorophenyl)methyl)-1H-imidazol-5-yl]methyl-2-benzylmalonate
5 (0.72 g, 1.36 mmol), potassium hydroxide (0.83 g, 14.7 mmol), water (15 mL) and ethanol (25 mL) was refluxed for 4 hours. The ethanol was evaporated, the residual aqueous layer was extracted with diethyl ether, and the basic solution was adjusted to pH 3.75 with
10 concentrated hydrochloric acid. The precipitated product was extracted into methylene chloride, dried, and concentrated. This crude product was flash chromatographed on silica gel with 10% methanol in methylene chloride to give 0.51 g (86%) of 3-[2-n-butyl-
15 1-((2-chlorophenyl)methyl)-1H-imidazol-5-yl]-2-benzylpropanoic acid; mp 118-120°C (from acetone/diethyl ether as the hydrochloride salt).

The procedure of Example 3 is illustrative of the
20 synthesis of compound encompassed by generic formula (IV).

Example 3

3-[2-n-Butyl-1-((2-chlorophenyl)methyl)-1H-imidazol-5-yl]benzoic Acid

25 (i) 2-n-butyl-1-(trimethylsilyl)ethoxymethyl-imidazole

Hexane-washed 80% sodium hydride (1.45 g, 0.0483 mol) in dimethylformamide (80 mL) under argon was treated with a solution of 2-n-butylimidazole (5.45 g, 0.0439 mol) in dimethylformamide (14 mL) dropwise at
30 25°C and the reaction was stirred an additional hour. Then 2-(trimethylsilyl)ethoxymethyl chloride (SEM-Cl) (7.68 g, 0.0461 mol) was added, the mixture was stirred for 18 hours at ambient temperature and then partitioned
35 between ice water and ethyl acetate. The washed, dried, concentrated organic solution was chromatographed over

- 34 -

silica gel with 1:1 hexane in ethyl acetate to yield 10.8 g (96%) of 2-n-butyl-1-(trimethylsilyl)-ethoxymethyl-imidazole.

(ii) 2-n-butyl-5-tributyltin-1-(trimethylsilyl)ethoxymethylimidazole

A solution of 2-n-butyl-1-SEM imidazole (prepared above) (6.37 g, 0.025 mol) in ethyl ether (125 mL) was treated dropwise with n-butyl lithium (0.0255 mol, 10.2 mL of 2.5 M in hexane) under argon at room temperature. After being stirred for an additional 45 minutes, tributyltin chloride (8.83 g, 7.4 mL, 0.026 mol) was added dropwise. The suspension was stirred overnight, saturated ammonium chloride solution was added and the ether layer was separated, washed with brine, dried over sodium sulfate, concentrated and flash chromatographed over silica gel with 3:1 hexane/ethyl acetate to provide 11.3 g (83%) of 2-n-butyl-5-tributyltin-1-(trimethylsilyl)ethoxymethylimidazole.

(iii) methyl 3-trifluoromethanesulfonyloxy-benzoate

To a solution of methyl 3-hydroxybenzoate (1.73 g, 11.3 mmol), 4-dimethylaminopyridine (215 mg, 1.74 mmol), and 2,6-lutidine (2.0 mL, 16.6 mmol) in 60 mL of methylene chloride at -30°C was added trifluoromethanesulfonic anhydride (2.8 mL, 16.6 mmol). After stirring the reaction mixture for 10 min at -30°C, the cooling bath was removed and the reaction was stirred at ambient temperature for 4 hours. Saturated aqueous ammonium chloride solution was then added, the layers were separated and the aqueous layer was back extracted twice with methylene chloride. The combined organic extracts were dried with sodium sulfate and the methylene chloride was removed in vacuo. The residue was dissolved in ethyl acetate and washed with water, 10% aqueous hydrochloric acid solution, saturated sodium bicarbonate solution and brine. The organic extract was dried with magnesium sulfate and the solvent was removed

- 35 -

in vacuo. The crude product was flash chromatographed over silica gel eluting with 1:1 diethyl ether/hexane to give 3.13 (98%) of methyl 3-trifluoromethanesulfonyloxybenzoate.

5 (iv) methyl 3-[2-n-butyl-1-((trimethylsilyl)ethoxymethyl)-1H-imidazol-5-yl]benzoate

To a solution of 2-n-butyl-5-tributyltin-1-((trimethylsilyl)ethoxymethyl)imidazole (6.06 g, 11.1 mmol), methyl 3-trifluoromethanesulfonyloxybenzoate
10 (3.13 g, 11.0 mmol) in 53 mL of 1,4-dioxane at room temperature was added tetrakis(triphenylphosphine)palladium (0) (256 mg, 0.22 mmol). The reaction mixture was stirred under argon at room temperature for 10 minutes and then 2,6-di-t-butyl-4-
15 methylphenol (10 mg) was added. The reaction was heated at 100°C for 3.5 hours, cooled to room temperature and treated with 70 mL of diethyl ether and 65 mL of aqueous potassium fluoride solution. The reaction mixture was left stirring at room temperature for 17 hours and then
20 filtered through Celite®. The organic layer was washed with water and brine, dried over magnesium sulfate and concentrated in vacuo. The crude product was flash chromatographed over silica gel eluting with 3:1 ethyl acetate/hexane to give 2.88 g (67%) of methyl 3-[2-n-
25 butyl-1-((trimethylsilyl)ethoxymethyl)-1H-imidazol-5-yl]benzoate.

(v) methyl 3-[2-n-butyl-1-t-butoxycarbonyl-1H-imidazol-5-yl]benzoate

To a solution of methyl 3-[2-n-butyl-1-((trimethylsilyl)ethoxymethyl)-1H-imidazol-5-yl]benzoate (2.88 g, 7.41 mmol) in 35 mL of ethanol was added 35 mL of 5N aqueous hydrochloric acid solution. The reaction mixture was heated at 55°C for 25 hours and then an additional 20 mL of 5N aqueous hydrochloric acid
35 solution was added. The reaction mixture was heated at 70°C for one hour and then stirred at room temperature

SUBSTITUTE SHEET

- 36 -

for 66 hours. The ethanol was removed in vacuo and the resulting aqueous layer was neutralized with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate. The organic extract was dried with sodium sulfate and the solvent was removed in vacuo.

The residue (1.46 g, 5.65 mmol) was dissolved in methanol (40 mL) and was treated with triethylamine (5.2 mL, 37.3 mmol) and di-*t*-butyl dicarbonate (8.4 mL, 35.4 mmol) at room temperature for 42.5 hours. The mixture was concentrated in vacuo and the crude product was flash chromatographed over silica gel with a gradient of ethyl acetate in hexane (1:8 to 4:1) to give 800 mg (30%) of methyl 3-[2-*n*-butyl-1-*t*-butoxycarbonyl-1*H*-imidazol-5-yl]benzoate.

(vi) methyl (3-[2-*n*-butyl-1-((2-chlorophenyl)methyl)-1*H*-imidazol-5-yl]benzoate

To a stirred solution of trifluoromethanesulfonic anhydride (0.72 mL, 5.1 mmol) in methylene chloride (20 mL) held at -78°C under argon was added a solution of 2-chlorobenzyl alcohol (748 mg, 5.25 mmol) and diisopropylethylamine (810 mg, 6.26 mmol) in methylene chloride (25 mL). After stirring for 15 minutes at -78°C, a solution of methyl (3-[2-*n*-butyl-1-*t*-butoxycarbonyl-1*H*-imidazol-5-yl]benzoate (1.53 g, 4.26 mmol) in methylene chloride (10 mL) was added dropwise over 10 minutes and the mixture was stirred overnight at room temperature. A solution of 5% sodium bicarbonate solution was added with stirring and the layers were separated, washed and dried. The reaction mixture was evaporated to dryness, the residue triturated with 1:1 hexane/ethyl acetate, the solid filtered off and the filtrate was concentrated and flash chromatographed over silica gel with 1:1 hexane/ethyl acetate to provide 600 mg (38%) of methyl (3-[2-*n*-butyl-1-((2-chlorophenyl)methyl)-1*H*-imidazol-5-yl]benzoate.

(vii) 3-[2-*n*-butyl-1-((2-chlorophenyl)methyl)-1*H*-

- 37 -

imidazol-5-yl]benzoic acid

Methyl 3-[2-n-butyl-1-{(2-chlorophenyl)methyl}-1H-imidazol-5-yl]benzoic (600 mg, 1.63 mmol) was dissolved in 6 mL of ethanol and then 2 mL of 10% aqueous sodium hydroxide solution was added. The reaction mixture was stirred at room temperature overnight, 10% aqueous hydrochloric acid solution was added to pH 3.5 and the resulting solid was filtered, washed with water and dried to give 125 mg (21%) of 3-[2-n-butyl-1-{(2-chlorophenyl)methyl}-1H-imidazol-5-yl]benzoic acid as the hydrochloride salt; mp 200-202°C.

The procedures of Example 4 is illustrative of the synthesis of compounds encompassed by generic formula (V).

Example 4

5-Bromo-2-n-butyl-1-(2-chlorophenyl)methyl-1H-benzimidazole-7-carboxylic Acid

(i) 2,5-dibromo-3-nitrobenzoic acid

The procedure described in R.K. Bentley and F.G. Holliman, J. Chem. Soc. (c), 2447 (1970) was used. A mixture of 2,5-dibromobenzoic acid (50 g, 0.18 mol) in concentrated sulfuric acid was vigorously stirred as fuming nitric acid (62.5 mL) was added dropwise at a rate to keep the temperature below 70°C. The reaction mixture was vigorously stirred, heated to 100°C and then kept at 100°C for 5 hours. The cooled reaction was cautiously poured into 2 liters of ice and vigorously stirred, the precipitate was filtered through a sintered glass funnel and the solid was washed well with water. Crystallization was achieved by dissolving the solid in acetic acid (150 mL) and after concentration to a half of the volume, crystals separated (16.72 g); mp 225-229°C. An additional crop of 7.52 g was obtained to give a total yield of 24.24 g (41%).

(ii) 5-bromo-2-[(2-chlorophenyl)methyl]amino-3-

- 38 -

nitrobenzoic acid

A suspension of 2,5-dibromo-3-nitrobenzoic acid (10.76 g, 0.0331 mol) in toluene (100 mL) was placed under argon, treated with 2-chlorobenzylamine (14.06 g, 0.0993 mol) and the mixture was brought to reflux. A clear, red solution resulted and the solution was refluxed for 24 hours, cooled, poured into 5% sodium hydroxide solution (600 mL) and ether (100 mL). The insoluble material was filtered off, the layers separated and the aqueous phase was added to the insoluble material and acidified with 10% hydrochloric acid solution. The separated crystalline product was collected, washed with water and the solid was crystallized from a large volume of methanol to provide 7.85 g (61.5%) of the yellow crystalline 5-bromo-2-[(2-chlorophenyl)methyl]amino-3-nitrobenzoic acid; mp 159-161°C.

(iii) 5-bromo-2-[(2-chlorophenyl)methyl-N-valeryl]amino-3-nitrobenzoic acid

A solution of 5-bromo-2-[(2-chlorophenyl)methyl]-amino-3-nitrobenzoic acid (8 g, 0.021 mmol) in pyridine (100 mL) was cooled in ice under argon and valeryl chloride (5.5 g, 0.046 mol) was added. The mixture was heated at 45°C for 18 hours, poured into water, acidified with hydrochloric acid and the oily product was extracted into ethyl acetate. The organic extracts were washed with 10% hydrochloric acid solution and brine, and the dried, concentrated product afforded about 100% yield of the crude oil, 5-bromo-2-[(2-chlorophenyl)methyl-N-valeryl]-amino-3-nitrobenzoic acid, which was used without further purification.

(iv) 5-bromo-2-n-butyl-1-(2-chlorophenyl)methyl-1H-benzimidazole-7-carboxylic acid

A solution of 5-bromo-2-[(2-chlorophenyl)methyl-N-valeryl]amino-3-nitrobenzoic acid (9.72 g, 0.0207 mol) in tetrahydrofuran (75 mL) was diluted with 5% sodium

- 39 -

bicarbonate solution (75 mL), and then treated portionwise with sodium hydrosulfite (12 g) over 2 hours. The pH was adjusted to 7.1 with additional solid sodium bicarbonate. After an hour of stirring, 6 g of additional sodium hydrosulfite was added, and, after another hour of stirring, the mixture was filtered, diluted with ether, and the layers were separated. The organic phase was concentrated to a solid that was dissolved in acetic acid (15 mL) and concentrated hydrochloric acid (5 mL) and heated on a steam bath for 2 hours. The residual slurry was concentrated in vacuo, diluted with water and the solid was collected. The solid was dissolved in hot methanol, some insolubles filtered off, and the filtrate was concentrated to incipient crystallization. After chilling, there was obtained 4.26 g (37%) of 5-bromo-2-n-butyl-1-(2-chlorophenyl)methyl-1H-benzimidazole-7-carboxylic acid; mp 254-255°C.

Example 5

An oral dosage form for administering orally active Formula (I) compounds is produced by screening, mixing and filling into hard gelatin capsules the ingredients in proportions, for example, as shown below.

| <u>Ingredients</u> | <u>Amounts</u> |
|--|----------------|
| (E)-3-[2-n-butyl-1-{(4-carboxy-phenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid | 100 mg |
| magnesium stearate | 10 mg |
| lactose | 100 mg |

Example 6

The sucrose calcium sulfate dihydrate and orally active Formula (I) compounds are mixed and granulated with a 10% gelatin solution. The wet granules are screened, dried, mixed with the starch, talc and stearic

- 40 -

acid, screened and compressed into a tablet.

| <u>Ingredients</u> | <u>Amounts</u> |
|---|----------------|
| (E)-3-[2-n-propyl-1-{(4-carboxynaphth-1-yl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid | 75 mg |
| calcium sulfate dihydrate | 100 mg |
| sucrose | 15 mg |
| starch | 8 mg |
| talc | 4 mg |
| stearic acid | 2 mg |

Example 7

- 5 (E)-3-[2-n-Butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid, 50 mg, is dispersed in 25 ml of normal saline to prepare an injectable preparation.


- 10 It is to be understood that the invention is not limited to the embodiments illustrated hereabove and the right to the illustrated embodiments and all modifications coming within the scope of the following claims is reserved.

- 41 -

What is claimed is:

1. A method of treating diabetic nephropathy in a mammal which comprises administering to a subject in need thereof an effective amount of an angiotensin II receptor antagonist.

2. The method of claim 1 which comprises administering an angiotensin II receptor antagonist of the formula:



20 in which:

R^1 is adamantyl, phenyl, biphenyl, or naphthyl, with each aryl group being unsubstituted or substituted by one to three substituents selected from Cl, Br, F, I, $\text{C}_1\text{-C}_6$ alkyl, nitro, $\text{A-CO}_2\text{R}^7$, tetrazol-5-yl, $\text{C}_1\text{-C}_6$ alkoxy, hydroxy, $\text{SC}_1\text{-C}_6$ alkyl, SO_2NHR^7 , NHSO_2R^7 , SO_3H , CONR^7R^7 , CN , $\text{SO}_2\text{C}_1\text{-C}_6$ alkyl, NHSO_2R^7 , $\text{PO}(\text{OR}^7)_2$, NR^7R^7 , NR^7COH , $\text{NR}^7\text{COC}_1\text{-C}_6$ alkyl, $\text{NR}^7\text{CON}(\text{R}^7)_2$, NR^7COW , W, SO_2W ;

m is 0-4;

R^2 is $\text{C}_2\text{-C}_{10}$ alkyl, $\text{C}_3\text{-C}_{10}$ alkenyl, $\text{C}_3\text{-C}_{10}$ alkynyl, $\text{C}_3\text{-C}_6$ cycloalkyl, or $(\text{CH}_2)_{0-8}$ phenyl unsubstituted or substituted by one to three substituents selected from $\text{C}_1\text{-C}_6$ alkyl, nitro, Cl, Br, F, I, hydroxy, $\text{C}_1\text{-C}_6$ alkoxy, NR^7R^7 , CO_2R^7 , CN, CONR^7R^7 , W, tetrazol-5-yl, $\text{NR}^7\text{COC}_1\text{-C}_6$ alkyl, NR^7COW , $\text{SC}_1\text{-C}_6$ alkyl, SO_2W , or $\text{SO}_2\text{C}_1\text{-C}_6$ alkyl;

X is a single bond, S, NR^7 , or O;

SUBSTITUTE SHEET

- 42 -

R^3 is hydrogen, Cl, Br, F, I, CHO, hydroxymethyl, COOR⁷, CONR⁷R⁷, NO₂, W, CN, NR⁷R⁷, or phenyl;

R^4 and R^5 are independently hydrogen, C₁-C₆alkyl, thienyl-Y-, furyl-Y-, pyrazolyl-Y-, imidazolyl-Y-,
 5 pyrrolyl-Y-, triazolyl-Y-, oxazolyl-Y-, isoxazolyl-Y-, thiazolyl-Y-, pyridyl-Y-, or tetrazolyl-Y-, except that R^4 and R^5 are not both selected from hydrogen and C₁-C₆alkyl and each heterocyclic ring is unsubstituted or substituted by C₁-C₆alkyl, C₁-C₆alkoxy, Cl, Br, F, I,
 10 NR⁷R⁷, CO₂R⁷, SO₂NHR⁷, SO₃H, or CONR⁷R⁷, OH, NO₂, W, SO₂W, SC₁-C₆alkyl, SO₂C₁-C₆alkyl, NR⁷COH, NR⁷COW, or NR⁷COC₁-C₆alkyl;

Y is a single bond, O, S, or C₁-C₆alkyl which is straight or branched or optionally substituted by phenyl
 15 or benzyl, wherein each of the aryl groups is unsubstituted or substituted by halo, NO₂, CF₃, C₁-C₆alkyl, C₁-C₆alkoxy, CN, or CO₂R⁷;
 R^6 is -Z-COOR⁸ or -Z-CONR⁷R⁷;

Z is a single bond, vinyl, -CH₂-O-CH₂-, methylene
 20 optionally substituted by C₁-C₆alkyl, one or two benzyl groups, thienylmethyl, or furylmethyl, or -C(O)NHCHR⁹-, wherein R^9 is H, C₁-C₆alkyl, phenyl, benzyl, thienylmethyl, or furylmethyl;

W is C_nF_{2n+1}, C_nF_{2n+1}, wherein n is 1-3;
 25 A is -(CH₂)_m-, -CH=CH-, -O(CH₂)_n-, or -S(CH₂)_n-; each R^7 independently is hydrogen, C₁-C₆alkyl, or (CH₂)_m phenyl, wherein m is 0-4; and
 R^8 is hydrogen, C₁-C₆alkyl, or 2-di(C₁-C₆alkyl)-amino-2-oxoethyl; or a pharmaceutically acceptable salt
 30 thereof.

3. The method of claim 2 wherein the angiotensin II receptor antagonist is (E)-3-[2-n-butyl-1-{4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid or a pharmaceutically acceptable salt thereof.

- 43 -

4. The method of claim 3 wherein the angiotensin II receptor antagonist is (E)-3-[2-n-butyl-1-((4-carboxyphenyl)methyl)-1H-imidazolyl-5-yl]-2-(2-thienyl)methyl-2-propenoic acid methanesulfonate.

5. The method of claim 2 wherein the angiotensin II receptor antagonist is (E)-3-[2-n-butyl-1-(4-carboxynaphth-1-yl)methyl]-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 wherein the angiotensin II receptor antagonist is:

(E)-3-[2-n-butyl-1-((4-carboxyphenyl)methyl)-1H-imidazol-5-yl]-2-n-butyl-2-propenoic acid;

(E)-1-[2-n-butyl-1-((4-carboxyphenyl)methyl)-1H-imidazol-5-yl]-2-(1H-tetrazol-5-yl)-3-(2-thienyl)-1-propene; or

N-[(1-(4-carboxyphenyl)methyl)-2-n-butyl-1H-imidazol-5-yl)methyl]-β-(2-thienyl)alanine; or a pharmaceutically acceptable salt thereof.

7. The method of claim 1 wherein the angiotensin II receptor antagonist 2-n-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl)-imidazole or a pharmaceutically acceptable salt thereof.

8. The method of claim 1 wherein the angiotensin II receptor antagonist is 2-n-propyl-4-pentfluoroethyl-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof.

9. The method of claim 1 wherein the angiotensin II receptor antagonist is 5,7-dimethyl-2-ethyl-3-(2'-

- 44 -


(tetrazol-5-yl)biphenyl-4-yl)methyl-3H-imidazo[4,5-b]pyridine or a pharmaceutically acceptable salt thereof.

5 10. The method of claim 1 wherein the angiotensin II receptor antagonist is 2-methyl-4-{(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methoxy}quinoline or a pharmaceutically acceptable salt thereof.

10 11. The method of claim 1 wherein the angiotensin II receptor antagonist is 2-n-butyl-4-chloro-1-{[3-bromo-2-[2-(tetrazol-5-yl)phenyl]benzofuranyl-4-yl)methyl}imidazole-5-acetic acid or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/GB 91/02220

| | | |
|--|---|-------------------------------------|
| I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ | | |
| According to International Patent Classification (IPC) or to both National Classification and IPC Int.C1.5 A 61 K 31/41 A 61 K 31/415 | | |
| II. FIELDS SEARCHED | | |
| Minimum Documentation Searched ⁷ | | |
| Classification System | Classification Symbols | |
| Int.C1.5 | A 61 K 31/00 | |
| Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸ | | |
| | | |
| III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ | | |
| Category ^o | Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹² | Relevant to Claim No. ¹³ |
| X | EP,A,0323841 (E.I. DU PONT DE NEMOURS AND CO.) 12 July 1989, see pages 75-79 (cited in the application) ----- | 1-11 |
| P,X | WO,A,9114367 (E.I. DU PONT DE NEMOURS AND CO.) 3 October 1991, see page 25, lines 1-17 ----- | 1-11 |
| P,X | EP,A,0403158 (SMITHKLINE BEECHAM CORP.) 19 December 1990, see abstract; claims; & CA,A,2018443 (14 December 1990) ----- | 1-11 |
| P,X | EP,A,0403159 (SMITHKLINE BEECHAM CORP.) 19 December 1990, see abstract; pages 7-9; claims; & CA,A,2018438 (14 December 1990) ----- | 1-11 |
| <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>^o Special categories of cited documents : ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div> | | |
| IV. CERTIFICATION | | |
| Date of the Actual Completion of the International Search | Date of Mailing of this International Search Report | |
| 20-03-1992 | 23 APR 1992 | |
| International Searching Authority | Signature of Authorized Officer | |
| EUROPEAN PATENT OFFICE |  MISS T. TAZELAAR | |

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET**V. ☒ OBSERVATION WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹**

This International search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim numbers _____ because they relate to subject matter not required to be searched by this Authority, namely:

Remark: although the claims are directed to a method of treatment of the human or animal body, the search has been carried out based on the alleged effects of the compounds.

2. ☒ Claim numbers **1-11(partially)** because they relate to parts of the International application that do not comply with the prescribed requirements to such an extent that no meaningful International search can be carried out, specifically:

A compound cannot sufficiently be described by its pharmac-activity alone (claim 1).

In view of the large number of compounds, which are defined

3. ☐ Claim numbers _____ because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this International application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International search report covers all searchable claims of the International application
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the International application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210 (supplemental sheet (2))

by the general formula of claim 2, the search had to be restricted for economic reasons. The search was limited to the compounds mentioned in the claims.

The claimed therapeutic activity of the compounds are not supported by any pharmacological data. In no way is made clear, how the therapeutic activity for any of the compounds can be concluded.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 9102220
SA 54324

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on 17/04/92
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| EP-A- 0323841 | 12-07-89 | US-A- 5015651 | 14-05-91 |
| | | AU-A- 2777089 | 13-07-89 |
| | | JP-A- 1287071 | 17-11-89 |
| | | US-A- 5081127 | 14-01-92 |
| | | US-A- 5043349 | 27-08-91 |
| WO-A- 9114367 | 03-10-91 | None | |
| EP-A- 0403158 | 19-12-90 | AU-A- 5690390 | 20-12-90 |
| | | CA-A- 2018443 | 14-12-90 |
| | | CN-A- 1048039 | 26-12-90 |
| | | JP-A- 3115268 | 16-05-91 |
| EP-A- 0403159 | 19-12-90 | AU-A- 5690190 | 10-01-91 |
| | | CA-A- 2018438 | 14-12-90 |
| | | CN-A- 1048038 | 26-12-90 |
| | | JP-A- 3115278 | 16-05-91 |